27.4000.51% ( -0.140 )
Closed: Nov 20, 16:00:00 (EDT)Financials
Q3 FY2026 EarningsPFE Q3 FY26 delivered a strong beat on the bottom line, with Adjusted Diluted EPS of $0.87 exceeding the $0.74 consensus, despite revenues of $16.6B coming in slightly above the $15.9B expected. Growth was driven by a 32% operational surge in 'Launched and Acquired Products,' particularly Padcev and Eliquis, which successfully mitigated the anticipated 63% decline in Paxlovid sales. Management raised full-year 2026 revenue guidance to $62.0B - $64.0B and Adjusted EPS to $2.95 - $3.05, signaling confidence in non-COVID growth drivers and cost-realignment efficiency.
Financial report interval: 2026.06.30 - 2026.09.30
Overview: Pfizer(PFE) the Revenue is 16.58 B (-0.43%), Beat estimate;the EBIT is 5.908 B (+4.73%), Beat estimate;the EPS is 0.56 (-9.68%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
16.58B0.43%
15.86B4.75%
+0.72B4.32%
EBITExceed expectations
5.91B4.73%
5.28B6.44%
+0.63B11.17%
EPSExceed expectations
0.569.68%
0.482422.20%
+0.077612.52%
Upcoming earnings report - FY2026 Annual Earning Release
Available dateFeb 2, 2027
Estimate Revenue63.13B
Estimate EBIT21.83B
Estimate EPS1.5418
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly
